Imagion Biosystems Limited (ASX:IBX) has lodged a Final Director's Interest Notice (Appendix 3Z) for former director Ms Melanie Leydin after the timeframe required under ASX Listing Rule 3.19A.3, with the company attributing the late filing to an administrative oversight following her resignation on 30 October 2026.
Key Points
- Ms Melanie Leydin ceased to be a director of Imagion Biosystems on 30 October 2026
- The Appendix 3Z was not lodged within the prescribed timeframe due to an administrative oversight during the director cessation process
- At the date of her resignation, Ms Leydin held no securities in the company and had no direct interests in any contracts with the company
- The company stated it has reviewed and reinforced its internal compliance procedures following the oversight
Late Filing of Final Director's Interest Notice
Imagion Biosystems disclosed that the Appendix 3Z for Ms Melanie Leydin is being lodged after the time required under ASX Listing Rule 3.19A.3. The company said the requirement to lodge the notice following Ms Leydin's resignation was inadvertently overlooked during the director cessation process. The date of the last notice for Ms Leydin was recorded as 31 July 2024, according to the filing. The company described its existing arrangements under ASX Listing Rule 3.19B as including ongoing communication between directors, the Company Secretary, and relevant administrative personnel.
Ms Leydin's Securities and Interests at Resignation
According to the Appendix 3Z lodged with the filing, Ms Leydin held nil securities as a registered holder at the time she ceased to be a director. The notice also disclosed nil securities held in any other capacity, and nil interests in contracts to which the company was a party. The filing states that Ms Leydin's last director's interest notice prior to this final notice was dated 31 July 2024. The Appendix 3Z was submitted by the company as agent for the director for the purposes of section 205G of the Corporations Act.
Compliance Procedures Reviewed Following Oversight
Imagion Biosystems stated that its arrangements under ASX Listing Rule 3.19B did not operate effectively in this instance, as the lodgement requirement was inadvertently overlooked. The company said it has reviewed and reinforced its internal compliance procedures to help ensure that all future notices required under ASX Listing Rule 3.19A.3 are lodged within the prescribed timeframe. The company stated it remains committed to complying with its obligations under the ASX Listing Rules and considers the measures taken appropriate to minimise the risk of a recurrence. The filing was authorised by the Board of Imagion Biosystems Limited.



Please wait processing your request...